Business, energy, technology, markets and global industry news from Business News Today

cancer diagnostics

PharmaDeviceNews cancer diagnostics
Representative image: Clinicians review a chest CT scan as AI-assisted lung nodule risk assessment gains attention through Tanner Health’s Optellum rollout, highlighting the push to improve early lung cancer triage in regional care.
Medical Devices & Diagnostics

Why Optellum’s deployment at Tanner Health could matter for lung cancer risk stratification

Find out how Tanner Health’s Optellum rollout could reshape AI lung nodule triage and early lung cancer detection in regional care.

Read More
Representative image of an AI-enabled precision oncology research meeting, illustrating how SOPHiA GENETICS and Memorial Sloan Kettering Cancer Center could turn cancer data into a precision medicine engine.
Medical Devices & Diagnostics

Can SOPHiA GENETICS and Memorial Sloan Kettering turn oncology data into a precision medicine engine?

SOPHiA GENETICS and Memorial Sloan Kettering aim to turn cancer data into precision oncology infrastructure. Can the hub deliver?

Read More
Representative image of clinicians reviewing genomic cancer testing data and medical imaging, reflecting Veracyte’s Prosigna and Decipher ASCO 2026 results and the growing role of precision oncology diagnostics in breast cancer and prostate cancer treatment decisions.
Medical Devices & Diagnostics

Can Veracyte’s Prosigna data change chemotherapy decisions in high-risk breast cancer?

Veracyte’s ASCO data could reshape chemotherapy decisions in breast and prostate cancer. Find out why genomic testing is gaining ground.

Read More
Representative image: AI-powered blood-based lung cancer screening is gaining momentum as DELFI Diagnostics secures New York approval for FirstLook Lung, expanding nationwide access to its laboratory-developed cancer detection test.
Medical Devices & Diagnostics

Why DELFI Diagnostics’ New York approval could shake up the lung cancer screening market

DELFI Diagnostics can now offer FirstLook Lung in all 50 states. Find out what this means for blood-based cancer screening.

Read More
Representative image: Veracyte’s Medicare coverage win for the TrueMRD bladder cancer recurrence monitoring test highlights the growing role of blood-based molecular diagnostics in detecting muscle-invasive bladder cancer recurrence earlier and supporting more precise post-treatment surveillance.
Medical Devices & Diagnostics

Why Veracyte’s Medicare win for TrueMRD could reshape bladder cancer recurrence monitoring

MRD testing has payer momentum, but clinical adoption is tougher. Veracyte’s TrueMRD Medicare win puts bladder cancer monitoring in focus.

Read More
Representative image: A precision oncology laboratory processes blood samples for molecular profiling, reflecting Caris Life Sciences’ Caris Assure submission to New York regulators for blood-based cancer testing authorization.
Medical Devices & Diagnostics

Can Caris Life Sciences turn Caris Assure into a broader precision oncology platform?

Caris wants New York access for Caris Assure. The bigger test is whether liquid biopsy scale can satisfy tougher state oversight.

Read More
Medical Devices & Diagnostics

Why PanGIA Biotech’s urine biopsy data may matter more than the headline sensitivity figure suggests

PanGIA Biotech reported 97.8% sensitivity in a urine-based prostate cancer study. Read what the data changes and what risks still remain.

Read More
Medical Devices & Diagnostics

Ibex–HNL Lab Medicine deal signals shift from digital pathology to embedded AI decision support in U.S. diagnostics

Ibex partners with HNL Lab Medicine to deploy AI in prostate cancer diagnostics. Discover what this means for pathology workflows and adoption.

Read More
Medical Devices & Diagnostics

How Exact Sciences is building a multi-platform cancer diagnostics case at AACR 2026

Exact Sciences presents Oncodetect MRD and Cancerguard MCED data at AACR 2026. Analysis of what the new TNBC and multi-biomarker classifier findings mean for clinical adoption.

Read More
Medical Devices & Diagnostics

How Adela’s tissue-free ctDNA methylation test could reshape monitoring of immunotherapy outcomes

Adela’s methylome blood test may help detect immunotherapy response earlier in cancer care. Discover what the latest study reveals for clinicians and diagnostics markets.

Read More